Veracyte, Inc.
VCYT
$28.61
-$0.46-1.58%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 479.13M | 463.39M | 445.76M | 425.33M | 399.58M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 479.13M | 463.39M | 445.76M | 425.33M | 399.58M |
| Cost of Revenue | 141.11M | 136.99M | 136.07M | 128.38M | 122.05M |
| Gross Profit | 338.02M | 326.41M | 309.70M | 296.96M | 277.53M |
| SG&A Expenses | 210.85M | 207.39M | 204.26M | 202.38M | 194.71M |
| Depreciation & Amortization | 13.90M | 14.40M | 14.85M | 15.80M | 17.34M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 436.71M | 429.82M | 424.47M | 415.24M | 398.53M |
| Operating Income | 42.42M | 33.57M | 21.30M | 10.09M | 1.05M |
| Income Before Tax | 28.97M | 35.08M | 25.74M | -8.17M | -54.79M |
| Income Tax Expenses | 2.63M | 2.03M | 1.61M | 1.10M | -750.00K |
| Earnings from Continuing Operations | 26.34 | 33.05 | 24.14 | -9.27 | -54.04 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.34M | 33.05M | 24.14M | -9.27M | -54.04M |
| EBIT | 42.42M | 33.57M | 21.30M | 10.09M | 1.05M |
| EBITDA | 65.40M | 56.80M | 44.76M | 33.63M | 26.04M |
| EPS Basic | 0.34 | 0.43 | 0.31 | -0.14 | -0.74 |
| Normalized Basic EPS | 0.46 | 0.36 | 0.25 | 0.21 | 0.11 |
| EPS Diluted | 0.33 | 0.41 | 0.30 | -0.15 | -0.75 |
| Normalized Diluted EPS | 0.46 | 0.36 | 0.25 | 0.20 | 0.11 |
| Average Basic Shares Outstanding | 311.04M | 309.19M | 305.92M | 301.42M | 297.21M |
| Average Diluted Shares Outstanding | 316.82M | 315.59M | 310.29M | 303.49M | 297.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |